Risk-on sentiment helps entire watchlist portfolio into the black
Markets are up including news that Nasdaq goes up 1.56%, trading at 12,100. S&P 500 up 0.83%, trading at 4,125.76.
Today's price action is taking place amid mixed market indicators – Producer Price Index in United States fell short of market expectations (0.1%) with a reading of -0.5%, continuing the decline from the previous figure of 0%.
“Top Movers” are assets that recorded the highest percentage change compared to their nearest peers. The currently most active stocks are listed below.
CRISPR Therapeutics | +16.06% in mid-session
After ending the previous day at $43.47, today the Swiss biotechnology company made its largest single-day jump of $7 (16.06%) since July 2022, and is now trading around $50.45. Approximately 8 months ago, the Swiss biotechnology company reached a significant high of $83.78 but has struggled to hold onto its gains and declined 48.11% since then. So far this year, it has been doing worse than the Nasdaq by 6.91%. The gene-editing biotech company's market cap currently stands at $3.97 billion with an average daily volume of 957,980 shares. CRISPR Therapeutics is forecasted to generate revenues of $1.62 million and EPS of $-2.32.
Marathon Digital Holdings, Inc. | +14.37% in mid-session
Marathon Digital Holdings, Inc. has posted further gains as part of a 5 day trend that has already seen the stock gain $2. Heading in the same direction for now — after closing yesterday at $9.95, the digital asset technology company went up to $11.65 only to drop back some of the way, and is now trading at $11.38.
Intellia Therapeutics leaps up to $38.95 up 12.64%
After closing yesterday at $34.58, the biotech company went up to $39.34 only to drop back some of the way, and is now trading at $38.95. The company is currently trading with a market cap of $3.43 billion with an average daily volume of 1 million shares. So far this year, it has been under-performing the Nasdaq by 13.13%.
Fate Therapeutics | +10.78% in mid-session
Fate Therapeutics has posted further gains as part of a 3 day trend that has already seen the stock gain 13 cents. As the session continues, it seems to maintain one direction — despite closing yesterday at $5.61 and then climbing as high as $6.26 today, Fate Therapeutics has given up a sizeable portion of its gains to now trade at $6.21.